Clinical Research Directory

Inclusion Criteria: * According to the world health organization (WHO) classification of newly diagnosed with AML patients; * Age ≥18 years old; * High-risk patients should meet any of the following criteria: ① High risk group according to the European Leukemia Risk stratification (ELN) 2022; (2) Secondary AML (sAML) which develops from myelodysplastic syndrome (MDS), bone marrow hyperplastic tumor (MPN) or chronic myeloid cell leukemia, et.; (3) Treatment-related AML (t-AML), Patients have a history of cytotoxic treatment record or ionizing radiation therapy. * Patients did not receive anti-AML therapy (except leukopenia therapy, such as hydroxyurea or cytarabine \< 1.0g/d) after the diagnosis of AML; * Expected survival ≥12 weeks; * The eastern tumor cooperation group (ECOG) score 3 points or less; * Kidney function: creatinine clearance acuity 30 ml/min; * Liver function: ALT \< 5 times normal value, bilirubin \< 3 times normal value; * Sign the informed consent form and understand and abide by the plan calls for process. Exclusion Criteria: * Acute promyelocytic leukemia; * With central nervous system leukemia (CNSL) ; * The cardiac function \> level 2; * The AIDS virus (HIV) infection; * Other clinical significance of uncontrolled condition, including but not limited to: (1) out of control, or active systemic infection (viruses, bacteria or fungi); (2) chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment; (3) need to actively deal with the merger of the second tumor; * Can't take oral treatment or having a gastrointestinal disease impact ing the absorption; * Being allergy to the experimental drugs; * Pregnant and lactating women; * Patients who could not understand or adhere to the study protocol; * Patients deemed by the investigator to be ineligible for enrollment.